MBRX - Moleculin's acute myeloid leukemia treatment gets EMA's orphan drug designation
2024-04-18 09:13:59 ET
More on Moleculin Biotech
- Moleculin Biotech, Inc. (MBRX) Q4 2023 Earnings Call Transcript
- Moleculin gets U.S. patent issue notification for annamycin targeting unmet need in AML
- Seeking Alpha’s Quant Rating on Moleculin Biotech
- Historical earnings data for Moleculin Biotech
- Financial information for Moleculin Biotech